ABSTRACT
The presence of five discrete synchronous or metachronous primary neoplasms in a single patient is an extremely rare event. This is a report of a patient with a malignant (invasive) thymoma and four other independent primary neoplasms including: gliosarcoma, papillary thyroid cancer, meningioma and metastatic adenocarcinoma of the colon, found synchronously at autopsy. Thymoma patients appear to have an inherent predisposition towards developing additional neoplasms. Other than the thymoma, the presented patient had no obvious risk factors for neoplasia. This case provides evidence for an unusual syndrome of thymoma and multiple primary neoplasms. Further research is required to elucidate the mechanism of this association. Meanwhile, heightened awareness of this association may allow earlier detection and treatment of additional cancers in patients with a history of thymoma.

INTRODUCTION
The development of five primary tumors in a single patient is extremely uncommon. Finding the five neoplasms synchronously is an extraordinarily rare event. Although cases of five or more synchronous primary tumors have been reported, these cases typically include multiple discrete tumors within the same or contralateral-paired organ. A patient who died of gliosarcoma and was found to synchronously have a total of five independent primary neoplasms including gliosarcoma, papillary thyroid cancer, meningioma, adenocarcinoma of the colon with hepatic metastases, and thymoma, is presented. Gliosarcoma itself is a highly aggressive, rarely encountered tumor of the central nervous system. Synchronous association of this unusual neoplasm with four other distinct neoplasms is exceptional, and to our knowledge, not previously reported. Such a peculiar array of multiple primary tumors appearing synchronously seems unlikely to be merely coincidental, but is suggestive of carcinogen exposure, or perhaps a sort of a “cancer syndrome.” This particular patient was without a history of carcinogen exposure, a prior personal history of cancer, or a familial predisposition. The presence of the thymoma is intriguing. A report from the Johns Hopkins Hospital found additional neoplasms in 31% of thymoma patients at some time during their follow-up. Other large series have similarly observed thymomas to be associated with additional non-thymic neoplasms with incidence rates ranging from 8% to 21%. Other than the thymoma, the patient had no obvious risk factors for neoplasia, providing further evidence for this unusual syndrome of thymoma and multiple primary malignancies.
CASE PRESENTATION

A female, 85 years of age, in good general health, presented to a local emergency department with an acute onset of left hemi-paresis. The patient was clinically diagnosed with an acute right cerebral hemispheric stroke. After being stabilized, the patient was transferred to Johns Hopkins Hospital for further management. Brain magnetic resonance imaging (MRI) identified a 3 x 2-cm right parietal lesion and a 1.5-cm right frontal lesion, both causing mass effect. Although the findings were compatible with hemorrhagic metastases, the differential diagnosis also included separate primary brain tumors. Radiographic studies including chest x-ray, bilateral mammogram, abdomen and pelvis were unremarkable. The carcinoembryonic antigen (CEA) was elevated to a level of 23 ng/ml. Other labs including thyroid function tests were within normal limits except for a slightly elevated alkaline phosphatase. Both the patient and her family decided to not pursue further work-up at that time. The patient was in stable condition and discharged home.

The patient's past medical history was notable for hypertension, mild dementia, depression, anemia, glaucoma and congestive heart failure. The patient had an aortic graft in the past, as well as a hysterectomy. There was no history of prior malignancy or family history of cancer. There was no record of carcinogen exposure.

The patient was readmitted two months later because of progressive left-sided hemi-paresis and mental status changes. Repeat brain MRI showed a large right hemispheric cystic tumor measuring 5.4 x 4 x 3 cm with massive peritumoral edema and mass effect, causing midline shift and subfalcine herniation. Given steady decline in performance status, the patient's family chose to only pursue supportive treatment. The patient was placed in hospice and died two months later.

Autopsy revealed 5 discrete primary tumors. The cause of death was attributed to a primary brain tumor, which was diagnosed as gliosarcoma by light microscopy and immunohistochemical staining. The patient was also noted to have a 2-cm, high-grade, poorly differentiated adenocarcinoma of the cecum invading through the muscularis and into the surrounding fat. Multiple liver metastases were found and attributed to the cecal primary. The third primary was a follicular variant of papillary thyroid carcinoma of the inferior right thyroid lobe measuring 1 x 1 x 1 cm. The fourth primary tumor was a right frontal lobe meningioma measuring 1.5 x 1 x 1 cm. The fifth and final primary was a malignant (invasive) thymoma, measuring 3 x 2 x 2 cm and extending into the anterior pericardial fat.

DISCUSSION

Multiple Neoplasms

Occult thyroid carcinomas found at autopsy are not rare. Autopsy series have revealed incidental thyroid cancers in about 10% of cases.3,10 Incidental meningiomas are also found in autopsy series at slightly over 1%.3 The probability of finding both in the same patient is simply the product of these two prevalences (0.1%). The likelihood of also simultaneously discovering a gliosarcoma, metastatic colorectal adenocarcinoma and invasive thymoma in the same patient is exceedingly small. A review of 140,000 cancer patients identified only one patient (0.0007%) with 5 discrete primary malignancies.12 Rohde and Jakse13 reviewed the literature on multiple primary malignant neoplasms and found 16 patients with 5 or more distinct primary tumors. Excluding cases in which separate tumors were reported in the same organ or in the contralateral-paired organ, only 10 patients with 5 or more discrete primary neoplasms, including their own case were identified. However, in 7 of these cases, the neoplasms developed metachronously, in contrast to the synchronous appearance in our case. The extreme rarity of the current case is suggestive of an underlying mechanism, rather than a mere chance association.

Etiology of Multiple Neoplasms

Gliosarcoma is considered a rare variant of glioblastoma multiforme, constituting 1.8% to 2.4% of glioblastoma cases in large series.14,15 It has been reported in association with prior exposure to ionizing radiation.6,16-17 Meningiomas18-20 and thyroid cancers21-23 likewise have been linked with radiation exposure. In addition to radiation, chemotherapy is well-known to be associated with secondary malignancies in cancer patients.24-27 The presented patient never received any radiotherapy or chemotherapy for symptomatic gliosarcoma or any of the tumors; thus, iatrogenic carcinogenesis can not explain the remarkable constellation of neoplasms.

Additional cancers are known to develop at a higher rate in people with a prior personal history of cancer. Patients with primary head and neck cancers occasionally develop additional tumors, presumably due to a history of heavy smoking and/or alcohol consumption, resulting in a “field cancerization” effect, predisposing the entire upper aerodigestive tract to additional cancers.28,29 The additional neoplasms in these cases are typically squamous cell carcinomas restricted to the upper aerodigestive system. The elevated risk of second cancers in patients with a personal history of cancer cannot always be explained by exogenous carcinogen exposure. Developmental and genetic factors play a role in some patients. Patients with ovarian and breast cancers are at higher risk for development of cancer in the contralateral paired organ, perhaps because of an endogenous hormonal imbalance and/or a genetic predisposition. While patients with Hodgkin’s disease occasionally develop second malignancies after cytotoxic therapies, a baseline analysis revealed abnormalities in sister chromatid exchange in some patients, which was independently predictive of the development of a second cancer.30 These abnormalities were identified before any treatment was administered. Treatment itself was not found to be an independent risk for second cancers, supporting the notion of an inherent predisposition to neoplasia in patients with Hodgkin’s disease. Well-studied inherited mutations such as p53 (Li-Fraumeni syndrome), p53 mismatch-repair genes in Lynch syndromes32 and Rb protein (p105-RB), in retinoblastoma,33 predispose individuals...
and their families to a variety of multiple malignancies. This patient did not have a history of smoking, alcohol abuse, carcinogen exposure, or a personal or family history of cancer. However, the patient did have a thymoma.

**Thymoma and Additional Neoplasms**

Several series have confirmed an increased incidence of thymoma and additional neoplasms (table 1), with prevalence rates as high as 31%. The discovery of multiple synchronous neoplasms along with thymoma has also been reported in the veterinary literature. In a study of 23 dogs with thymoma, additional neoplasms were concurrently found among 5 dogs (22%), paralleling the human observations. In people, thymoma has been found to be associated with additional malignant neoplasms of various sorts, most notably colorectal adenocarcinoma and thyroid cancer. At the Mayo Clinic, Souadjian et al. found that 21% of 146 thymoma patients developed second malignancies. This was compared and contrasted with an 8% second malignancy rate among 177 patients with parathyroid tumors. Their review of the literature revealed a reported second malignancy incidence of 17% among patients surviving beyond 5 years after diagnosis of thymoma. The true incidence of additional malignancies was higher, as cases with simultaneously diagnosed lymphoma or leukemia were excluded to avoid potential confusion between thymoma and secondary lymphocytic infiltration of the thymus. Interestingly, this population (thymoma plus leukemia or lymphoma) accounted for a high proportion (10%) of the 588 evaluable patients, a finding observed by others. In Taiwan, Pan et al. also found an increased risk of second malignancies among thymoma patients. In their study, the second malignancy incidence rate among thymoma patients was significantly higher compared to a matched cohort of patients with nasopharyngeal carcinoma (8% vs. 2%). The largest single series reporting thymoma and additional neoplasms was conducted by Lewis et al. who reviewed the Mayo Clinic experience and revealed a second malignancy rate of 17% (48 of 283), corroborating the prior work of Souadjian et al. A recent review confirmed a 17% (152 of 909) incidence of second malignancies in patients with thymoma with colorectal carcinomas representing the most common site. The current review resulted in an identical 17% figure (table 1).

**Treatment-Induced Malignancies**

As the early reports did not specify treatment for the thymomas, the possibility of treatment-induced neoplasia remained. Welsh et al. showed that the high incidence of additional neoplasms in thymoma patients cannot be attributed to adjuvant radiotherapy or chemotherapy and appears to be an intrinsic association. Of 142 thymoma patients, 46 received radiation or chemotherapy. Among these 46 patients, 16 (35%) developed second neoplasms. This did not differ significantly from the prevalence of second neoplasms in those who did not receive radiation or chemotherapy (25%), or the thymoma population as a whole (28%). Conversely, of the 38 patients with additional neoplasms, only 16 received radiation or chemotherapy, while 22 did not. Among patients who received radiotherapy and developed additional neoplasms, the second tumors usually developed outside the radiation fields, a finding confirmed by others, which strongly argues against a link to radiotherapy. Finally, as in the present case, the other tumors were often diagnosed shortly after, synchronously, or even before the thymoma, again not consistent with treatment-induced neoplasia. Thus, radiation or chemotherapy apparently does not account for the high rate of additional neoplasms in thymoma patients.

Because of the integral role of the thymus in immunity, one may speculate that surgical removal of the thymus may be predisposing thymoma patients to additional malignancies. However, Bulkley et al. observed no increase in malignancies among patients who underwent thymic resection for myasthenia gravis, except when the myasthenia gravis was accompanied by thymoma. Similarly, Masaoka et al. analyzed 390 patients with myasthenia gravis who had undergone thymic resections and found no increase in the extrathymic malignancy rate among those without an associated thymoma. In contrast, patients with thymoma and myasthenia gravis who underwent thymic resection had an observed-to-expected malignancy ratio of 3:42. Pan et al. also found a higher rate of additional tumors in patients undergoing thymectomy for thymoma (8%) compared to patients who had thymectomy for myasthenia gravis alone (2%). Thus surgical resection of the thymus for myasthenia gravis apparently does not increase the chances of developing cancer.

**Table 1. Series involving more than 50 patients with thymoma and reporting data on prevalence of additional malignancies.**

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of patients</th>
<th>Institution</th>
<th>Prevalence</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lewis et al.4</td>
<td>283</td>
<td>Mayo Clinic</td>
<td>48/283</td>
<td>17%</td>
</tr>
<tr>
<td>Pan et al.5</td>
<td>192</td>
<td>Veterans General Hospital, Taipei, Taiwan</td>
<td>15/192</td>
<td>8%</td>
</tr>
<tr>
<td>Welsh et al.1</td>
<td>142</td>
<td>Johns Hopkins Hospital</td>
<td>44/142</td>
<td>31%</td>
</tr>
<tr>
<td>Gray and Gutowski3</td>
<td>54</td>
<td>New York Hospital</td>
<td>5/54</td>
<td>9%</td>
</tr>
<tr>
<td>Couture and Mountain2</td>
<td>52</td>
<td>University of Texas, M.D. Anderson Cancer Center</td>
<td>11/52</td>
<td>21%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>723</strong></td>
<td></td>
<td><strong>123/723</strong></td>
<td><strong>17%</strong></td>
</tr>
</tbody>
</table>

*Other series from the literature were excluded if their patient population was included in the larger series from the same institution.*
**Associated Paraneoplastic Disorders**

The paraneoplastic conditions typically linked with thymoma such as myasthenia gravis, red cell aplasia and hypogammaglobulinemia represent immunological disorders and thus could conceivably be related to the higher rates of cancer either intrinsically, or because of immunosuppressive therapy for the autoimmune disorder. The presented patient did not have any obvious thymoma-associated paraneoplastic immunological phenomena. Wilkins et al.\(^8\) and others,\(^1\) found that the presence or absence of paraneoplastic immunological disorders did not appear to influence the development of further neoplasms. Of 67 patients with immunological disorders, only 24% developed additional tumors–no greater than in the total thymoma population studied (38 of 135 [28%]) or in the thymoma patients without associated disorders (21 of 68 [31%]). Thus, the presence of (or treatment for) such thymoma-associated conditions cannot entirely explain the high malignancy rate.

**Multiple Malignancies Associated with Thymoma**

The finding of multiple malignancies in human patients\(^1,5,39\) and in dogs\(^34\) with thymoma supports the concept of an inherent, rather than coincidental link between thymoma and cancer. This strong oncogenic tendency among patients with thymoma is illustrated by a review by Freidman et al.\(^39\) in which a third discrete malignancy developed in 33% of patients with a history of thymoma and a hematologic neoplasm. Very similar findings were reported from Johns Hopkins,\(^1\) where 58 additional neoplasms were found in 44 thymoma patients. A total of 14 patients (31%) were found to have 3 or more discrete primary tumors either synchronously, or metachronously during follow-up. Our present case with 5 synchronous distinct primary neoplasms provides an extreme example of this susceptibility.

**Pathogenesis**

A precise pathogenic mechanism linking thymoma to an increased incidence of cancer remains elusive. Studies have demonstrated histologic differences in thymic tissue from cancer patients compared to normal controls.\(^40\) Although this may implicate thymic function in some way; it is unclear if this is a cause or effect relationship. The authors postulated that development of thymoma implies a defect in thymic epithelium that hinders T-cell development, leading to immune defects and a higher incidence of cancer. Some thymoma patients reportedly have peripheral T-cell lymphocytosis, which may reflect a perturbation of systemic immunoregulation that accompanies thymic neoplasia.\(^41\) Such immune dysfunction could theoretically lead to a breakdown in immune surveillance allowing uncontrolled proliferation of neoplasms, which would otherwise be kept in check. Skinnider et al.\(^36\) have suggested that decreased natural killer cell function resulting from increased suppressor T-cell activity could be causally linked to the increased incidence of cancer in patients with thymoma. Freidman et al.\(^39\) proposed that the thymoma epithelium may continuously stimulate T-lymphocytes, which in turn predisposes to neoplasia. While this may account for cases of hematologic malignancies, it does not adequately explain the various solid tumors encountered, nor does it explain the tumors observed before or synchronously with the thymoma.

Although cytogenetic abnormalities have been reported in thymoma,\(^44,45\) presently no molecular or cytogenetic mechanisms adequately explain the tendency of thymoma patients to acquire additional neoplasms. Interestingly, patients with Hodgkin’s disease also have a high incidence of second malignancies.\(^25,27\) While it is assumed that this high incidence of additional malignancies is due to radiation or chemotherapy, baseline cytogenetic studies of patients with Hodgkin’s disease before treatment have identified abnormalities in sister chromatid exchange as an independent risk factor for second primary cancers.\(^30\) Occasionally, Hodgkin’s disease occurs synchronously with other neoplasms, suggesting that like thymoma, some of these patients have an intrinsic predisposition towards additional cancers.\(^42\) Curiously, as this case, a patient with Hodgkin’s disease as one of 5 distinct predisposition towards additional cancers.\(^43\)

**CONCLUSION**

The presence of 5 or more distinct metachronous primary neoplasms in a single patient is a very rare event. The detection of 5 or more primary neoplasms simultaneously in a single patient is extraordinary. There is now convincing evidence of a syndrome associating thymoma with additional cancers. Most cases of second malignancies appear metachronously, with an overall prevalence of 17%. Adenocarcinomas of the gastrointestinal tract appear most frequently but a wide array of different histologies has been observed. The precise pathogenic mechanism remains unclear. We suspect that the presented patient’s thymoma was related to the multiple neoplasms by either inducing a proclivity towards neoplasia or serving as a marker for an inherent propensity for neoplasia. Although medical texts routinely describe the classic associations of thymoma with myasthenia gravis, pure red cell aplasia, and hypogammaglobulinemia, there is also an important association between thymoma and malignant neoplasms. The existence of this syndrome is illustrated by this case and is supported by a review of the medical and veterinary literature. For patients with a past history of thymoma, awareness of this association should allow earlier detection and treatment of any future cancers through proper surveillance.

**ACKNOWLEDGMENTS**

The authors gratefully acknowledge and appreciate the assistance of Anne Kammer of the Johns Hopkins Tumor Registry.
REFERENCES


